Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: A twelve-week, randomized, placebo-controlled study

Diabetes, Obesity and Metabolism

Volumn 1, Issue 3, 1999, Pages 165-172

  Patel, J ^b   Anderson, R J ^a   Rappaport, E B ^b  

^a VA NEBRASKA WESTERN IOWA HEALTH CARE SYSTEM   (United States)

^b NONE

Author keywords

Glycaemia; Rosiglitazone; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; C PEPTIDE; CHOLESTEROL; FRUCTOSAMINE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; ROSIGLITAZONE; THIAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; BODY WEIGHT; C-PEPTIDE; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; FRUCTOSAMINE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; LIPIDS; MALE; MIDDLE AGED; PLACEBOS; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0033123466     PISSN: 14628902     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1463-1326.1999.00020.x     Document Type: Article

References (25)

1. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM: a balanced overview. Diabetes Care 1992; 15: 318-368.
2. Morici ML, Di Marco A, Sestito D et al. The impact of coexistent diabetes on the prevalence of coronary heart disease. J Diabetes Compl 1997; 11: 268-273.
3. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the multiple risk factor-intervention trial. Diabetes Care 1993; 16: 434-444.
4. Barzilay JI, Kronmal RA, Bittner V, Eaker E, Foster ED. Coronary artery disease in diabetic and nondiabetic patients with lower extremity arterial disease: a report from the Coronary Artery Surgery Study Registry. Am Heart J 1998; 135: 1055-1062.
5. Perneger TV, Brancati FL, Whelton PK, Klag MJ. End-stage renal disease attributable to diabetes mellitus. Ann Intern Med 1994; 121: 912-918.
6. United Kingdom Prospective Diabetes Group. UK Prospective Diabetes Study 30: diabetic retinopthy at diagnosis of type 2 diabetes and associated risk factors. Arch Ophthalmol 1998; 116: 297-303.
7. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
8. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
9. Pirart J. Tight glycaemic control prevents diabetic complications. Acta Clin Belg 1995; 50: 321-325.
10. Cantello BCC, Cawthorne MA, Cottam GP et al. [[ω-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents. J Med Chem 1994; 37: 3977-3985.
11. Young PW, Buckle DR, Cantello BC et al. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma. J Pharmacol Exp Ther 1998; 284: 751-759.
12. Eldershaw TP, Rattigan S, Cawthorne MA, Buckingham RE, Colquhoun EG, Clark MG. Treatment with the thiazolidinedione (BRL 49653) decreases insulin resistance in obsese Zucker hindlimb. Horm Metab Res 1995; 27: 169-172.
13. Smith S, Boam D, Cawthorne MA et al. Rosiglitazone improves insulin sensitivity and reduces hyperexpression of insulin and amylin mRNAs in pancreatic islets. Diabetes 1998; 47: A94.
14. Oakes ND, Kennedy CJ, Jenkins AB, Laybutt DR, Chisholm DJ, Kraegen EW. A new antidiabetic agent, BRL 49653, reduces lipid bioavailability and improves insulin action and glucoregulation in the rat. Diabetes 1994; 43: 1203-1210.
15. Hulin B, McCarthy PA, Gibbs EM. The glitazone family of antidiabetic agents. Curr Pharmaceut Design 1996; 2: 85-102.
16. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J Biol Chem 1995; 270: 12953-12956.
17. Forman BM, Chen J, Evans RM. The peroxisome proliferator-activated receptors: ligands and activators. Ann NY Acad Sci 1996; 804: 266-275.
18. Adams M, Montague CT, Prins JB et al. Activators of peroxisome-proliferator-activated receptor γ have depot-specific effects on human preadipocyte differentiation. J Clin Invest 1997; 100: 3149-3153.
19. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979; 28: 1039-1057.
20. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
21. Maggs DG, Buchanan TA, Durant CF et al. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study. Ann Intern Med 1998; 128: 176-185.
22. Ghazzi MN, Perez JE, Antonucci TK et al. Cardiac and glycaemic benefits of troglitazone treatment in NIDDM. Diabetes 1997; 46: 433-439.
23. Kumar S, Boulton AJM, Beck-Nielsen H et al. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia 1996; 39: 701-709.
24. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996; 45: 1661-1669.
25. Paolisso G, Howard BV. Role of non-esterified fatty acids in the pathogenesis of type 2 diabetes mellitus. Diabet Med 1998; 15: 360-366.